Compare Deckers Outdoor Corp (DECK) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deckers Outdoor Corp vs Pfizer Inc — how do they compare? Deckers Outdoor Corp trades at $82.62 (market cap $10.95B), while Pfizer Inc trades at $27.83 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 14.6× Deckers Outdoor Corp's market cap, and Pfizer Inc pays a 6.14% dividend while Deckers Outdoor Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deckers Outdoor Corp for 71 Days and Pfizer Inc for 158 Days on average.
| DECK | PFE | |
|---|---|---|
Market Cap | $10.95B | $159.59B |
Volume | 3,090,240 | 30,937,010 |
Sector | Consumer Cyclical | Health |
52-Week High | $120.94 | $29.02 |
52-Week Low | $77.51 | $23.67 |
Typical Hold Time | 71 Days | 158 Days |
Enterprise Value | $9.82B | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deckers Outdoor (DECK) trades at $80.38, down 1.57% today, with strong fundamentals including 19.37% net margin and consistent earnings beats. The stock shows neutral technical signals with support at $78-79 and resistance at $81-82. Revenue growth has accelerated from $3.2B in 2022 to $5.0B in 2025, while profitability metrics remain robust with 42.56% ROE.
DECK presents a compelling value opportunity with attractive valuation multiples (P/E 11.43, EV/EBITDA 7.06) and 46% upside to consensus price target of $117.13. Risks include potential margin pressure from competitive footwear market and projected negative cash flow in 2026. Analyst sentiment leans bullish with 45% buy ratings versus 11% sell recommendations.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
